Precision Biosciences Inc financial data

Symbol
DTIL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
302 East Pettigrew Street, Suite A 100, Durham, North Carolina
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 352 % +6.32%
Debt-to-equity 322 % +4.19%
Return On Equity 42.5 %
Return On Assets 10.1 %
Operating Margin -8.32 % +82.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.23M shares -93.7%
Common Stock, Shares, Outstanding 7.12M shares -93.8%
Entity Public Float 59.1M USD -65.3%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 6.97M shares +83.2%
Weighted Average Number of Shares Outstanding, Diluted 7.01M shares +84.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 87.6M USD +88.4%
Research and Development Expense 59.8M USD +119%
General and Administrative Expense 35.1M USD -14.5%
Operating Income (Loss) -7.29M USD +66.7%
Net Income (Loss) Attributable to Parent 17M USD
Earnings Per Share, Basic 0.32 USD/shares
Earnings Per Share, Diluted 0.29 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 124M USD -10.3%
Accounts Receivable, after Allowance for Credit Loss, Current 207K USD -68.3%
Other Assets, Current 790K USD +57.1%
Assets, Current 144M USD -2.59%
Deferred Income Tax Assets, Net 3.28M USD +181%
Property, Plant and Equipment, Net 4.23M USD -76.8%
Operating Lease, Right-of-Use Asset 7.69M USD +62.9%
Intangible Assets, Net (Excluding Goodwill) 375K USD -75.8%
Other Assets, Noncurrent 234K USD -62.2%
Assets 166M USD -8.75%
Accounts Payable, Current 1.14M USD +46.5%
Employee-related Liabilities, Current 2.48M USD -29.2%
Contract with Customer, Liability, Current 526K USD -97.8%
Liabilities, Current 33M USD -41.6%
Contract with Customer, Liability, Noncurrent 26.8M USD -65.7%
Deferred Income Tax Liabilities, Net 3.28M USD +181%
Operating Lease, Liability, Noncurrent 7.09M USD +123%
Other Liabilities, Noncurrent 766K USD +253%
Liabilities 91.1M USD -38.3%
Retained Earnings (Accumulated Deficit) -448M USD +3.65%
Stockholders' Equity Attributable to Parent 74.7M USD +119%
Liabilities and Equity 166M USD -8.75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19M USD +39.7%
Net Cash Provided by (Used in) Financing Activities 40.1M USD +5311%
Net Cash Provided by (Used in) Investing Activities -26K USD +96.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 7.15M shares -93.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 21.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 124M USD -10.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 526K USD +13.4%
Deferred Tax Assets, Valuation Allowance 139M USD +14.6%
Operating Lease, Liability 8.31M USD +46.6%
Lessee, Operating Lease, Liability, to be Paid 10.4M USD +62.9%
Property, Plant and Equipment, Gross 31.8M USD -5.52%
Operating Lease, Liability, Current 1.22M USD -51.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.02M USD +90.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD -6.88%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.11M USD +190%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.08M USD +90.6%
Deferred Tax Assets, Operating Loss Carryforwards 45.5M USD +24.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.14M USD +188%
Operating Lease, Payments 462K USD -19.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 11.9M USD -32.5%
Interest Expense 2.29M USD +16.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%